

CASE REPORT

Isolated lymph nodal recurrence after 10 years in FIGO Stage IA1 cervical adenocarcinoma treated with conization: case report and review of the literature

Doi: 10.36129/jog.2022.84

Martina **Arcieri** ^{1,*}, Canio **Martinelli** ², Stefano **Cianci** ², Roberta **Granese** ¹, Giuseppe **Vizzielli** ³, Pasquale **Fatuzzo** ⁴, Alfredo **Ercoli** ²

¹ Department of Biomedical, Dental, Morphological and Functional Imaging Science, University of Messina, 98122 Messina, Italy.

² Department of Human Pathology in Adult and Childhood "G. Barresi", University of Messina, 98122 Messina, Italy.

³ Clinic of Obstetrics and Gynaecology, Department of Medical Area (DAME), University of Udine, "Santa Maria della Misericordia" Hospital, Azienda Sanitaria Ospedaliera Friuli Centrale, 33100 Udine, Italy.

⁴ UOC Ostetricia e Ginecologia, Hospital Gravina Caltagirone, ASP 3, Sicilia, Italy.

***Corresponding author:** Martina Arcieri. Department of Biomedical, Dental, Morphological and Functional Imaging Science, University of Messina, 98122 Messina, Italy

Tel.: + 390902212158/+393478114704; martina.arcieri@unime.

iD ORCID

Martina Arcieri: <https://orcid.org/0000-0002-8257-0618>

Canio Martinelli: <https://orcid.org/0000-0002-0587-8467>

Stefano Cianci: <https://orcid.org/0000-0002-0548-9891>

Roberta Granese: <https://orcid.org/0000-0003-0318-9390>

Giuseppe Vizzielli: <https://orcid.org/0000-0002-2424-2691>

Alfredo Ercoli: <https://orcid.org/0000-0002-5019-5526>

ABSTRACT

Background. Cervical cancer (CC) represents the fourth most common cancer in women. Since about 25% of women with CC has 40 years or less, more and more women choose fertility-sparing surgery (FSS). FSS, such as conization, represents valid and safe procedures for patients with IA1 tumors without lymph-vascular involvement (LVSI); It has been established that, for this very early stage, the risk of node involvement is negligible (~ 1 %), that is why nodal staging can be skipped

and definitive conization can be considered a curative treatment. The issue is that a wide consensus regarding the most appropriate follow-up protocols after FSS has not been achieved.

Case presentation. It is reported a very unusual recurrence of cervical adenocarcinoma that is characterized by the site of metastasis that occurred at nodal level, instead of the most common recurrence site that is the cervix, and for the “time to recurrence” that was astonishing long because it occurred at 10 years after conization. Only English studies and those performed in humans were considered to compare the case study to the actual literature. 10 eligible studies were found.

Conclusions. Undoubtedly, because of the rarity of the event, it is not possible to reach a clear conclusion. However, the analysis of this case report could be an opportunity to generate new hypothesis about natural history of the disease and to question the safety of FSS when applied outside the actual indications. It is of paramount importance to never lower our guard even on the very early stages, focusing on oncological secondary prevention. It reflects the importance of build a stricter follow up for these patients until new strong medical evidence will be showed.

Keywords: Uterine Cervical Neoplasms; conization; neoplasm recurrence; adenocarcinoma; fertility sparing surgery

Introduction

Cervical cancer (CC) represents the fourth most common cancer in women, and it is an important public health problem affecting middle-aged women [1]. According to international guidelines, the standard treatment of early cervical cancer is radical surgery [2,3]. However, considering that more than 25% of women with CC have 40 years or less [4] and that the mean age of the new mother is advancing, It has become mandatory to consider fertility-sparing surgery (FSS) in this very peculiar population. Undeniably, according to international guidelines, FSS may be proposed in selected women with FIGO [5] stage IA or stage IB1 lesions (less than 2-cm diameter) who desire preserving their fertility [2,3]. A recent review of the literature showed that, after FSS, the mean recurrence rate was 3.2% while the mean cancer death rate was 0.7% [6].

Among FSS procedures, conization represents a valid and safe procedure for patients with IA1 tumors without lymph-vascular involvement (LVSI); moreover, since the risk of lymph node involvement is negligible (~ 1 %) in this subset of patients, nodal staging can be skipped and definitive conization with negative resection margins can be considered a curative treatment in almost 100% of cases [7].

After FSS, there has not been achieved a wide consensus regarding the most appropriate follow-up protocols because the case numbers remain low, and no prospective randomized trial are carried out.

Following we report a case of an unusual, isolated lymph node-relapse of FIGO Stage IA1 cervical adenocarcinoma at 10 years after conization. A review of the literature was conducted by combing disease-specific terms (uterine cervix neoplasms AND adenocarcinoma AND microinvasive) with treatment-specific terms (conservative therapy, fertility sparing surgery, conization) in MEDLINE and EmBase up to March 2022. Our research particularly focused on recurrence ratio after conization. We found 10 studies.

Case presentation

Past medical history: In July 2010, a 36-year-old woman with a diagnosis of FIGO IA1 cervical adenocarcinoma G1 was submitted to FSS (conization). Negative LVSI and margin of resection

resulted to the definitive pathological finding; subsequently, she underwent to a regular clinical follow-up every six months during the subsequent 5 years. In 2013, she conceived spontaneously but, unfortunately, she had a miscarriage. Subsequent routine gynecological screening was negative.

Suspected diagnosis of disease recurrence: In September 2020, at 46-years-old, after a negative HPV and Pap-test, the gynecological clinical visit highlighted a right parauterine mass; the magnetic resonance imaging (MRI) and computer tomography scan (CT scan) confirmed a mm 30x30x37 multilocular mass as suspected metastatic right iliac lymph node (Figure 1). After this finding, she was referred to the Gynecologic Oncology Unit of the AOU "G. Martino" of Messina. Unfortunately, an ultrasound-guided biopsy did not lead to a differential diagnosis. Thus, after a multidisciplinary board discussion and after a dedicated counselling with the woman, surgery was chosen as the best approach to obtain both a histological diagnosis and a curative effort.

Surgery: In October 2020, the patient was submitted to exploratory laparoscopy to exclude carcinosis, intraperitoneal masses and visceral metastases and to perform a biopsy of the suspected metastatic lymph node. Metastatic glandular cells were confirmed at the intraoperative pathological diagnosis using frozen sections. Therefore, in the same surgical session, the patient underwent open abdominal type C1 radical hysterectomy with bilateral salpingo-oophorectomy, bilateral pelvic lymph node dissection, right distal ureteral resection with its reimplantation. Since the right ureter appeared closely attracted from the bulky lymph-node, the surgeon (AE) decided to sacrifice the distal portion of the ureter in order to obtain clean macroscopic resection margins. The histopathological finding showed a metastatic lymph-node from the cervical cancer, but the cervix was completely negative. In the metastatic lymph node, HPV16 was detected. The patient was discharged uneventfully 1 week after surgery and received subsequent external radiotherapy. The only complication experienced was a urinary infection treated efficiently with oral antibiotics.

Adjuvant therapy: From the sixth month after the end of the radiotherapy, the patient experienced multiple intestinal sub occlusive episodes treated conservatively and a major depressive disorder, with deterioration of general conditions. In January 2022, due to intestinal occlusion, she was submitted to exploratory laparotomy with no evidence of macroscopic disease and the general surgeon performed adhesiolysis and multiple biopsies. The histopathologic report was negative, but she died in March 2022 due to cachexia. **Figure 1.**

Discussion and review of the literature

The report describes an unusual case of cervical cancer relapse after FSS whose atypical features include I) the elapsed time from the first diagnosis to relapse, considering the initial FIGO stage; II) the negative pathological finding of the cervix after surgical definitive approach.

The latest FIGO classification (2018) defines stage IA1 of cervical cancer as an invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion <3 mm. The horizontal dimension is not considered in the 2018 classification as it is subject to many artifactual errors [5]. The FIGO cancer report had indicated that with normal follow-up at 5 years, the patient, treated for FIGO IA cervical cancer, can return to routine screening schedule [5]. FIGO IA1 cervical cancers have an excellent prognosis and literature data reports very few cases of relapses, treated using either FFS or standard surgery. A recent review of the literature reported a recurrence rate of 0.2% after FSS in FIGO stage IA1 cervical carcinoma [8].

In a systematic review of published literature, Hou et al reported a survival rate of 99% for microinvasive adenocarcinoma of the cervix for FIGO stage IA1 and a survival rate of 98% for IA2 and a recurrence rate after FSS of 3.4% and 2.2%, respectively [9]. Spoozak et al showed survival rate similar for conization and hysterectomy for both FIGO stage IA1 squamous cell carcinomas and adenocarcinomas. The authors analyzed 554 cases of stage IA1 adenocarcinoma of the cervix subdivided into 433 women submitted to hysterectomy and 121 to conization: the 5-year

survival was 96.9% for hysterectomy compared with 98.8% for conization. The limit of this study is the lack of the recurrence incidence [10]. Lee et al reported no cases of recurrence after conization for IA1 squamous cervical cancer, concluding that conization alone with careful follow-up appears to be an effective and safe treatment for patients with stage IA1 microinvasive carcinoma, regardless of resection margins status or LVSI [11]. Likewise, Baalbergen [12], McHale [13], Poyner [14], Reynolds [15] and Yahata [16] did not reported any cases of relapses in their series after conization in stage IA1 cervical adenocarcinoma, highlighting the relevance of clear margins. Also, Baalbergen et al analyzed 59 cases of cervical microinvasive adenocarcinoma including 22 patients underwent FSS. In FSS group, no case of recurrence was reported while in the hysterectomies group, the authors recorded 1 case of lymph-nodal relapse after 30 months: a woman with positive LVSI treated by vaginal hysterectomy [12]. Ceballos et al analyzed 32 cases of IA1 adenocarcinoma submitted to both standard and FSS treatment and no relapses were reported after a mean follow-up of 54 months [17]. Instead, MacNab et al reported one case of recurrence of stage IA1 cervical cancer after large loop excision of the transformation zone (LLETZ). This woman had negative cytology at 6 and 12-months after treatment. She was admitted for abdominal pain 18 month-after LLETZ and she was diagnosed a large ovarian mass, ascites and pleural effusion. She was submitted to cytoreduction surgery, and the final histology confirmed a metastatic adenocarcinoma of the cervix [18]. Singh et al reported a case of microinvasive cervical adenocarcinoma treated with conization that has developed a large endometrial localization 33 months after FSS and died for metastatic disease 49 months after cone biopsy [19].

Elliot et al. analyzed 476 cases of stage IA carcinoma of the cervix, highlighting more recurrence in older patients, in case of glandular cancer and tumors invading > 3 mm, while LVSI didn't seem to impact on prognosis. However, in this last case-series, there was a case of a young women with characteristics like ours: cervical adenocarcinoma invading 0.1 mm with negative LVSI, treated with a conization. After 8 months, she was submitted to extrafascial hysterectomy with lymphadenectomy because of positive smear at follow-up schedule. The final histology revealed a solitary positive pelvic lymphonode; unfortunately, she died 8 years later for upper abdominal and cerebral metastasis [20]. In literature, most recurrences occur within the first 24 months. Few cases of recurrence were reported 5 years after primary FSS, and in almost all cases several factors increase risk of relapse of early cervical cancer: tumor dimension, depth of stromal invasion, grade and presence of LVSI [12,21]. It is important to consider that our patient did not have any of these risk factors.

Also, usually, the early cervical cancers, especially in case of stage IA1, recur at the level of the cervix after FSS. The depth of invasion is a major risk factor for recurrence in cervical adenocarcinoma. Hirai et al analyzed 302 patients with early cervical adenocarcinomas and concluded that invasive cervical adenocarcinoma with a depth of invasion of 3 mm or less and a horizontal spread of 7 mm or less has little potential for nodal metastasis or recurrence. Among 22 patients with IA1 adenocarcinoma cervical cancer treated with radical hysterectomy, they reported one case of recurrence on vaginal wall 45 months after first treatment [22]. Berek et al reported an absence of incidence of lymphonode metastasis in patients with an adenocarcinoma of the cervix that had a depth invasion of less than 2, while positive lymphnode were found in 11.1% patients with 2-5 mm of invasion [23].

Furthermore, Sopracordervole et al has concluded their manuscript, about a series of microinvasive adenocarcinoma treated by FSS, highlighting that conization can be safe in women with stage IA1 with clear margins and no LVSI. However, women should be informed about the risk of recurrence considering the low reliability of follow-up techniques (cytology, colposcopy, and endocervical curettage). FSS should be indicated only in patients with strongly desire of offspring [24,25]. **Table 1.**

The relationship between high-risk HPV subtype infections and cervical cancer development is widely accepted, while the correlation between HPV expression and disease relapse is still unclear. There are 15 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) that are typically associated with cervical cancer [26].

It has been reported in literature, that there is a highly variable prevalence of HPV DNA in pelvic lymph nodes of patients with cervical cancer, ranging between 25% and 80% [27]. In most articles, it is highlighted how metastatic pelvic lymph nodes tend to be HPV positive. In 2019, Chen et al analyzed the presence of HPV DNA in cervical tissues and lymph nodes in 88 patients submitted to surgery for invasive cervical cancer with lymphatic metastases. They retrospectively assessed 88 patients with uterine cervical neoplasms with lymph node metastases and in 82 (93.2%) cases, they found HPV DNA in both the cervical tissues and pelvic lymph nodes [28]. A recent meta-analysis highlighted as the use of prophylactic HPV vaccination as an adjunct to surgical excision for CIN 2 or greater reduces the risk of recurrent disease (OR 0.36; 95% CI 0.22–0.57; $p < 0.0001$ [29]). Perhaps if our patient had undergone conization in the vaccination era, it could have reduced her recurrence risk. This is even more true when we look at the recent data regarding the risk of preneoplastic lesion recurrence: the persistence of HPV after FSS is the principal risk factor for recurrence [33] and HPV vaccination after FSS (conization) is associated with a reduce risk of CIN 2 recurrence [34].

In the very early stages, our goal is achieving a definitive oncological cure by surgery only reducing the recurrence risk to an absolute 0%. Although the emerging literature shows that there are therapeutic possibilities to preserve the quality of life and sexual discomfort during and after any adjuvant therapy [30,31,32], avoiding radiotherapy and chemotherapy by reducing recurrences of disease to 0% remains the main absolute goal.

To our knowledge, this is the first case available in literature of lymph node recurrence 10-years after conization in FIGO IA1 cervical cancer. Because of the rarity of this event, it is impossible to draw definitive conclusions, but it still provides an interesting and cardinal insight: nowadays, in the era of personalized medicine, it should be mandatory in all patients, even in those who seem to have a low recurrence rate, to pursue a very deep investigation of the disease till its molecular factors. These conclusions are in line with a very recent editorial conducted by D’Oria where it is reported that an accurate prediction of treatment response and survival based on all the personal features of the woman affected by cervical carcinoma including its molecular analysis, will help to implement personalized therapies that may improve the treatment of cervical cancer patients [35].

Conclusion

We reported a very unusual recurrence of cervical adenocarcinoma submitted to FSS that is distinguished by the site of metastasis that occurred at nodal level, instead of the most common recurrence site that is the cervix, and for the “time to recurrence” that was astonishing long because it occurred at 10 years after conization. Moreover, we reviewed cases of relapse after conization in cervical adenocarcinoma FIGO stage IA1 submitted to FSS in the literature. Undoubtedly, because of the rarity of this event, it is not possible to come to a clear conclusion. Similarly this case report shows that an isolated nodal recurrence of cervical cancer at 10 years after FSS, still rare, is possible and it could cause a domino effect that lead to death. The case reported highlights the importance of never lower our guard even on the very early stages. It could be an opportunity to generate new hypothesis about natural history of this disease. Although we still consider FSS a possible option for very early stages in selected cases, we recommend to build a stricter follow up and to offer a more personalized reproductive counselling for these patients until new strong medical evidence will be showed.

Compliance with Ethical Standards

Authors contribution:

Each author contributed remarkably to the article. Ideation and conceptualization of the case was led by A.E., M.A.; G.V defined the methodology; data curation was up to C.M. and P.F.; formal analysis was made by M.A. and C.M., investigation was driven by A.E., M.A and G.V, project administration was done by A.E. and A.M.; A.E. and S.C. supervised, validation was cured by A.E. and M.A., writing – original draft was edited by M.A., G.V., writing – review & editing was up to C.M. and R.G.. No Funding needed for this project. All the authors declare no conflict of interest.

Funding:

This research received no external funding.

Ethical approval:

Not applicable.

Informed consent:

The patient provided written informed consent to the collection and analysis of her data for scientific purposes.

Data sharing:

The article describes entirely theoretical research.

Disclosure of interests

This research received no external funding.

REFERENCES

1. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Health*. 2020;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6.
2. Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. *Radiother Oncol*. 2018;127(3):404-416. doi: 10.1016/j.radonc.2018.03.003.
3. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, et al. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. *J Natl Compr Canc Netw*. 2020;18(6):660-666. doi: 10.6004/jnccn.2020.0027.
4. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998-2003. *Cancer*. 2008;113(10 Suppl):2855-64. doi: 10.1002/cncr.23756.

5. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. *Int J Gynaecol Obstet.* 2018;143 Suppl 2:22-36. doi: 10.1002/ijgo.12611.
6. Nezhat C, Roman RA, Rambhatla A, Nezhat F. Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer: a systematic review. *Fertil Steril.* 2020;113(4):685-703. doi: 10.1016/j.fertnstert.2020.02.003.
7. He Y, Wu YM, Zhao Q, Wang T, Wang Y, Kong WM, et al. Clinical value of cold knife conization as conservative management in patients with microinvasive cervical squamous cell cancer (stage IA1). *Int J Gynecol Cancer.* 2014;24(7):1306-11. doi: 10.1097/IGC.000000000000199.
8. Schuurman T, Zilver S, Samuels S, Schats W, Amant F, van Trommel N, et al. Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review. *Cancers (Basel).* 2021;13(5):1008. doi: 10.3390/cancers13051008.
9. Hou J, Goldberg GL, Qualls CR, Kuo DY, Forman A, Smith HO. Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis. *Gynecol Oncol.* 2011;121(1):135-42. doi: 10.1016/j.ygyno.2010.11.036.
10. Spoozak L, Lewin SN, Burke WM, Deutsch I, Sun X, Herzog TJ, et al. Microinvasive adenocarcinoma of the cervix. *Am J Obstet Gynecol.* 2012;206(1):80.e1-6. doi: 10.1016/j.ajog.2011.07.029.
11. Lee SW, Kim YM, Son WS, You HJ, Kim DY, Kim JH, et al. The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma. *Acta Obstet Gynecol Scand.* 2009;88(2):209-15. doi: 10.1080/00016340802596009.
12. Baalbergen A, Smedts F, Helmerhorst TJ. Conservative therapy in microinvasive adenocarcinoma of the uterine cervix is justified: an analysis of 59 cases and a review of the literature. *Int J Gynecol Cancer.* 2011;21(9):1640-5. doi: 10.1097/IGC.0b013e3182262059.
13. McHale MT, Le TD, Burger RA, Gu M, Rutgers JL, Monk BJ. Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. *Obstet Gynecol.* 2001;98(5 Pt 1):726-31. doi: 10.1016/s0029-7844(01)01544-7.
14. Poynor EA, Marshall D, Sonoda Y, Slomovitz BM, Barakat RR, Soslow RA. Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization. *Gynecol Oncol.* 2006;103(3):960-5. doi: 10.1016/j.ygyno.2006.05.041.
15. Reynolds EA, Tierney K, Keeney GL, Felix JC, Weaver AL, Roman LD, et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. *Obstet Gynecol.* 2010;116(5):1150-7. doi: 10.1097/AOG.0b013e3181f74062.
16. Yahata T, Nishino K, Kashima K, Sekine M, Fujita K, Sasagawa M, et al. Conservative treatment of stage IA1 adenocarcinoma of the uterine cervix with a long-term follow-up. *Int J Gynecol Cancer.* 2010;20(6):1063-6. doi: 10.1111/IGC.0b013e3181e768b6.
17. Ceballos KM, Shaw D, Daya D. Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis. *Am J Surg Pathol.* 2006;30(3):370-4. doi: 10.1097/01.pas.0000186398.18206.ff.
18. MacNab WS, Holdsworth TF, Lindsay R, Shanbhag S, Siddiqui N, Burton K. The Current Burden of Follow-up of Stage 1A1 Cervical Cancer. *J Low Genit Tract Dis.* 2017;21(4):268-271. doi: 10.1097/LGT.0000000000000333.
19. Singh P, Scurry J, Proietto A. Lethal endometrial recurrence after cone biopsy for microinvasive cervical adenocarcinoma. *J Obstet Gynaecol Res.* 2008;34(3):413-7. doi: 10.1111/j.1447-0756.2008.00787.x.

20. Elliott P, Coppleson M, Russell P, Liouros P, Carter J, MacLeod C, et al. Early invasive (FIGO stage IA) carcinoma of the cervix: a clinico-pathologic study of 476 cases. *Int J Gynecol Cancer*. 2000;10(1):42-52. doi: 10.1046/j.1525-1438.2000.00011.x.
21. Grisaru DA, Covens A, Franssen E, Chapman W, Shaw P, Colgan T, et al. Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma. *Cancer*. 2003;97(8):1904-8. doi: 10.1002/cncr.11269.
22. Hirai Y, Takeshima N, Tate S, Akiyama F, Furuta R, Hasumi K. Early invasive cervical adenocarcinoma: its potential for nodal metastasis or recurrence. *BJOG*. 2003 Mar;110(3):241-6.
23. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. *Ann Oncol*. 1999;10 Suppl 1:87-92. doi: 10.1023/a:1008323922057.
24. Sopracordevole F, Canzonieri V, Giorda G, De Piero G, Lucia E, Campagnutta E. Conservative treatment of microinvasive adenocarcinoma of uterine cervix: long-term follow-up. *J Low Genit Tract Dis*. 2012;16(4):381-6. doi: 10.1097/LGT.0b013e3182446b3a.
25. Bisseling KC, Bekkers RL, Rome RM, Quinn MA. Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. *Gynecol Oncol*. 2007;107(3):424-30. doi: 10.1016/j.ygyno.2007.07.062.
26. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med*. 2003;348(6):518-27. doi: 10.1056/NEJMoa021641.
27. Slama J, Fischerova D, Pinkavova I, Zikan M, Cibula D. Human papillomavirus DNA presence in pelvic lymph nodes in cervical cancer. *Int J Gynecol Cancer*. 2010;20(1):126-32. doi: 10.1111/IGC.0b013e3181c01cf0.
28. Chen P, Zhang W, Yang D, Zhang W, Gao S. Human Papillomavirus Status in Primary Lesions and Pelvic Lymph Nodes and Its Prognostic Value in Cervical Cancer Patients with Lymph Node Metastases. *Med Sci Monit*. 2019;25:1894-1902. doi: 10.12659/MSM.914564.
29. Di Donato V, Caruso G, Petrillo M, Kontopantelis E, Palaia I, Perniola G, et al. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. *Vaccines (Basel)*. 2021;9(5):410. doi: 10.3390/vaccines9050410.
30. G. Buzzaccarini, L. Marin, M. Noventa, A. Vitagliano, A. Riva, F. Dessole, et al; Hyaluronic acid in vulvar and vaginal administration: evidence from a literature systematic review, *Climacteric*, 2021, DOI: 10.1080/13697137.2021.1898580
31. D'Oria O, Giannini A, Buzzaccarini G, Tinelli A, Corrado G, Frega A, et al. Fractional Co2 laser for vulvo-vaginal atrophy in gynecologic cancer patients: A valid therapeutic choice? A systematic review. *Eur J Obstet Gynecol Reprod Biol*. 2022 Oct;277:84-89. doi: 10.1016/j.ejogrb.2022.08.012.
32. Tramacere F, Lancellotta V, Casà C, Fionda B, Cornacchione P, Mazzarella C, et al.; Assessment of Sexual Dysfunction in Cervical Cancer Patients after Different Treatment Modality: A Systematic Review. *Medicina (Kaunas)*. 2022 Sep 5;58(9):1223. doi: 10.3390/medicina58091223.
33. Bogani G, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Lopez S, et al; Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. *Gynecol Oncol*. 2020 Dec;159(3):636-641. doi: 10.1016/j.ygyno.2020.08.025.

34. Bogani G, Lalli L, Sopracordevole F, Ciavattini A, Ghelardi A, Simoncini T, et al.; Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia. *Vaccines (Basel)*. 2022 Apr 9;10(4):579. doi: 10.3390/vaccines10040579.
35. D'Oria O, Corrado G, Laganà AS, Chiantera V, Vizza E, Giannini A. New Advances in Cervical Cancer: From Bench to Bedside. *Int J Environ Res Public Health*. 2022 Jun 9;19(12):7094. doi: 10.3390/ijerph19127094.

Manuscript accepted for publication

Table 1. IA1 adenocarcinoma of the cervix treated with conization (attached: Figure and Table legend): No case of invasive cancer or distant localization, one case of adenocarcinoma in situ of the cervix 21 months after conization submitted simple hysterectomy as definitive therapy.

Author	Year	FIGO Stage	Cone	Relapse	Median DFS (months)
Singh ¹⁹ , 2008	/	IA1	1	1	33
Reynolds ¹⁵ , 2010	1983-2008	IA1	7	0	71
McHale ¹³ , 2001	1985-1996	IA1	4	0	48
Ceballos ¹⁷ , 2006	1985-2002	IA1	1	0	31
Bisseling ²⁵ , 2007	1987-2004	IA1	16	0	72
Baalbergen ¹² , 2011	1987-2006	IA1	15	0	79.9
Yahata ¹⁶ , 2010	1990-2004	IA1	10	0	75
Poynor ¹⁴ , 2006	1992-1999	IA1	3	0	30
Sopracordevole ²⁴ , 2012	1995-2007	IA1	4	0*	69
MacNab ¹⁸ , 2017	2007-2011	IA1	10	1	60
This case, 2020	2010-2020	IA1	1	1	120
Total	1983-2020	IA1	72	3 (4.2%)	64.5

Figure 1. Enhanced magnetic resonance image. An enhanced mass measuring 30x30x37 mm was detected at the right parametrium.



Manuscript accepted for publication